Login / Signup

Should patient enrollment criteria for anti-VEGF phase III trials be reconsidered.

Joel HanhartSohee JeonRaimo Tuuminen
Published in: Journal of diabetes (2023)
Keyphrases
  • phase iii
  • open label
  • clinical trial
  • double blind
  • vascular endothelial growth factor
  • case report
  • phase ii
  • placebo controlled
  • endothelial cells
  • health insurance
  • healthcare